Kenneth Abramowitz
HEALTH PLAN 2009

Kenneth Abramowitz

Kenneth S. Abramowitz is a senior adviser at the Carlyle Group, an investment company based in New York, and has served as managing director on Carlyle's Healthcare Team.

Much of today's discussion about employers getting out of the health care business focuses on contributions to workers for direct purchase of health care services, so-called consumer-driven health care plans. But there is a more effective type of defined contribution that few people are discussing. That better alternative also includes employer contributions, and also empowers employees to make choices, but from a menu of health insurance plans, not just health care services. I believe that model, for several reasons, more closely represents what employee health benefit plans will look like in five or six years.

The problem is that giving employees a pool of money to directly choose services won't save money or improve the quality of care. In spite of all the buzz about e-health — whether it's consumer research or companies promising to effectively guide health decisions — the vast majority of consumers will always lack the knowledge about diseases and appropriate care that is necessary to make cost-effective and quality choices.

What's more, the marketplace is deceptive: Choosing based on price is impossible for consumers to do intelligently because pricing offered by physicians and medical groups is misleading. The actual cost after all appropriate service, including lab tests, is usually much higher than is ever advertised.

And government intervention can't make consumers smarter. The tax-exempt health savings accounts created in the new Medicare law — which allow employees enrolled in company-sponsored health plans with high deductibles to open accounts they can use for doctor's visits, drugs, or whatever service they want — won't encourage intelligent decision-making or save money. The bottom line is that consumers lack the information necessary to use the money wisely. So consumer-driven care, as it being discussed today, will be a market failure.

In fact, it is in large measure because employers care about the quality of care — after all, they want the money they spend on health care to translate into healthy workers — that they will want to maintain influence over employee choice. The best way to do that is to negotiate with health plans about the quality and cost of services. In turn, these health plans negotiate with the providers.

Employers do know that. They know they have clout over price and quality, and notwithstanding current experiments with consumer choice, employers will not give up that influence for long. For example, in the next several years there will be an increased market emphasis on disease management program offerings by managed care plans, because employers will demand it.

That's the kind of intelligent, well-informed role employers will continue to play. They will negotiate with health plans to provide the best kind of care at the best price, because they have the human resource experience and personnel to do so effectively.

The defined-contribution concept will no doubt continue to grow, and some form of tax-exempt medical savings account that contains contributions from employers and employees may very well gain in popularity. But by 2009 — and probably much sooner — the money offered to employees for health care will be for choosing from a menu of health plans, whether they be tightly managed HMOs or less tightly managed PPOs or POS plans. Capitation has probably seen its day — providers have no more interest in assuming risk — but the role of managed health care will evolve into better disease management, improved treatment options, and an increased emphasis on preventive care.

Cost containment and quality will always be market drivers. It is employers who are best suited to negotiating with health plans to provide and/or negotiate for both. That isn't a matter of fashion, it's a fact today and tomorrow.

Managed Care’s Top Ten Articles of 2016

There’s a lot more going on in health care than mergers (Aetna-Humana, Anthem-Cigna) creating huge players. Hundreds of insurers operate in 50 different states. Self-insured employers, ACA public exchanges, Medicare Advantage, and Medicaid managed care plans crowd an increasingly complex market.

Major health care players are determined to make health information exchanges (HIEs) work. The push toward value-based payment alone almost guarantees that HIEs will be tweaked, poked, prodded, and overhauled until they deliver on their promise. The goal: straight talk from and among tech systems.

They bring a different mindset. They’re willing to work in teams and focus on the sort of evidence-based medicine that can guide health care’s transformation into a system based on value. One question: How well will this new generation of data-driven MDs deal with patients?

The surge of new MS treatments have been for the relapsing-remitting form of the disease. There’s hope for sufferers of a different form of MS. By homing in on CD20-positive B cells, ocrelizumab is able to knock them out and other aberrant B cells circulating in the bloodstream.

A flood of tests have insurers ramping up prior authorization and utilization review. Information overload is a problem. As doctors struggle to keep up, health plans need to get ahead of the development of the technology in order to successfully manage genetic testing appropriately.

Having the data is one thing. Knowing how to use it is another. Applying its computational power to the data, a company called RowdMap puts providers into high-, medium-, and low-value buckets compared with peers in their markets, using specific benchmarks to show why outliers differ from the norm.
Competition among manufacturers, industry consolidation, and capitalization on me-too drugs are cranking up generic and branded drug prices. This increase has compelled PBMs, health plan sponsors, and retail pharmacies to find novel ways to turn a profit, often at the expense of the consumer.
The development of recombinant DNA and other technologies has added a new dimension to care. These medications have revolutionized the treatment of rheumatoid arthritis and many of the other 80 or so autoimmune diseases. But they can be budget busters and have a tricky side effect profile.

Shelley Slade
Vogel, Slade & Goldstein

Hub programs have emerged as a profitable new line of business in the sales and distribution side of the pharmaceutical industry that has got more than its fair share of wheeling and dealing. But they spell trouble if they spark collusion, threaten patients, or waste federal dollars.

More companies are self-insuring—and it’s not just large employers that are striking out on their own. The percentage of employers who fully self-insure increased by 44% in 1999 to 63% in 2015. Self-insurance may give employers more control over benefit packages, and stop-loss protects them against uncapped liability.